[Company analysis] Takeda Pharmaceutical Company, Ltd. (武田薬品工業)

「Takeda Pharmaceutical Company, Ltd. (武田薬品工業)」is one of Japan's five largest pharmaceutical companies(「Takeda Pharmaceutical Company(武田薬品工業)」、「Astellas Pharma(アステラス製薬)」、「Daiichi Sankyo(第一三共)」、「Otsuka Holdings(大塚ホールディングス)」、「Eisai(エーザイ)」) and among them, this company has top class sales. In 2019, they bought a major Irish pharmaceutical company, 「Shire」, and became one of the world's top 10 largest pharmaceutical companies. The number of consolidated employees is about 27,230.

 

1. Company Profile

2. Summary and Features

3. Major Business

4. Financial Information

 

 

 

1. Company Profile

 

※Unit is JPY million, as of 2019

Company name	Takeda Pharmaceutical Company, Ltd.
Company name (Japanese)	武田薬品工業
Date of establishment	June 12, 1781
Headquarters location	〒103-8668 東京都中央区日本橋本町二丁目1番1号
Capital	77,900
Consolidated sales	2,097,224
Consolidated operating profit	204,969
Consolidated total assets	13,872,322
Consolidated capital	5,163,588
Capital adequacy ratio	37.2%
Consolidated number of employees	27,230

 

 

 

2. Summary and Features

 
「Takeda Pharmaceutical」 originated in 1781, when Takeda Chobei began trading herbal medicines in Doshomachi, Osaka, which was the center of Japan's drug trade. At that time, Takebe Chobei's business was a small intermediary store that purchased medicines from wholesalers, after sortting them with small bucket and sold them to local drugstores or doctors. In 1895, they entered the pharmaceutical business in earnest, and at that time this company built a dedicated factory in Osaka. In 1907, it succeeded in producing sugar for the first time in Japan, and in 1943, and changed the company name into current 「Takeda Pharmaceutical」.

Today,「Takeda Pharmaceutical」is a global pharmaceutical company with a focus on research and development, with approximately 90% of its total sales coming from pharmaceutical sales. Their main products are peptic ulcers (Antipeptic Ulcer Drug) and anticancer drugs. The company employs approximately 30,000 people in 70 countries around the world, and has a strong overseas business with an overseas sales ratio of 50%.

In the past, they engaged in non-pharmaceutical businesses such as pesticides, urethane resins, veterinary drugs, seasonings and vitamins, but from 2000 to 2007, each of these businesses was transfered to 「Sumitomo Chemical Co., Ltd.(住友化学)」, 「Mitsui Chemicals, Inc.(三井化学)」, 「Schering-Plough 」, 「Kirin Brewery(キリンビール)」. In addition, this company also conducted food business through their subsidiary, 「Takeda Food(武田食品工業)」, but as of April 3, 2006, they transfered all of their food and beverage business to「House Wellness Foods Co., LTD.(ハウスウェルネスフーズ株式会社)」which was established by  joint cooperation「House Food(ハウス食品)」and「Takeda Pharmaceutical」

Originally, this company was a typical Japanese company and had a corporate culture that emphasized teamwork and unity above all. But in June 2010, Christophe Weber took over the role of president, and「Takeda Pharmaceutical」started to promote globalization rapidly. Especially, they conducted large-scale takeovers with overseas companies such「Shire」, a major pharmaceutical company in Island. As a result, Takeda Pharmaceutical has become one of the world's top 10 pharmaceutical companies.

 

 

 

 

3. Major Business

 

■ Manufacture and sale of ethical drugs

 

 

 

4. Financial information

 

※Unit is JPY million

		2016	2017	2018
Consolidated sales		1,732,051	1,770,531	2,097,224
Consolidated operating profit		155,867	241,789	204,969
Consolidated total assets		4,346,794	4,106,463	13,872,322
Consolidated net assets		1,948,965	2,017,409	5,163,588
Breakdown of sales	Japan	655,344	580,349	571,000
	America	520,161	598,341	829,000
	Europe and Canada	279,693	313,723	405,600
	Russia and CIS	57,550	68,240	59,700
	South America	72,516	75,658	88,100
	Asia	112,799	104,026	105,400
	Others	33,987	30,194	38,300